Thrivent Financial for Lutherans Cuts Holdings in CareDx, Inc. $CDNA

Thrivent Financial for Lutherans cut its holdings in CareDx, Inc. (NASDAQ:CDNA) by 75.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,452 shares of the company’s stock after selling 38,218 shares during the quarter. Thrivent Financial for Lutherans’ holdings in CareDx were worth $181,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Allworth Financial LP purchased a new stake in shares of CareDx during the 2nd quarter worth $40,000. State of Alaska Department of Revenue purchased a new stake in CareDx during the third quarter worth about $43,000. Tower Research Capital LLC TRC boosted its holdings in CareDx by 120.6% during the second quarter. Tower Research Capital LLC TRC now owns 7,608 shares of the company’s stock worth $149,000 after buying an additional 4,160 shares in the last quarter. RiverPark Advisors LLC acquired a new position in CareDx during the second quarter worth about $149,000. Finally, AlphaQuest LLC increased its holdings in CareDx by 40.0% in the second quarter. AlphaQuest LLC now owns 9,576 shares of the company’s stock valued at $187,000 after buying an additional 2,736 shares in the last quarter.

Insider Transactions at CareDx

In other news, CEO John Walter Hanna, Jr. sold 19,280 shares of the business’s stock in a transaction dated Thursday, January 22nd. The stock was sold at an average price of $21.16, for a total transaction of $407,964.80. Following the completion of the sale, the chief executive officer owned 597,405 shares in the company, valued at approximately $12,641,089.80. The trade was a 3.13% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold a total of 29,636 shares of company stock worth $625,949 over the last ninety days. 4.40% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on CDNA. BTIG Research boosted their price target on CareDx from $22.00 to $25.00 and gave the stock a “buy” rating in a research note on Thursday, November 6th. Zacks Research upgraded CareDx from a “strong sell” rating to a “hold” rating in a research report on Tuesday, November 18th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of CareDx in a research note on Monday, December 29th. Wells Fargo & Company raised their target price on shares of CareDx from $14.00 to $18.00 and gave the company an “equal weight” rating in a report on Monday, December 15th. Finally, Wall Street Zen cut shares of CareDx from a “buy” rating to a “hold” rating in a research report on Saturday, February 7th. Three investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $26.67.

CareDx Stock Performance

Shares of CDNA stock opened at $19.87 on Friday. The firm has a market capitalization of $1.02 billion, a price-to-earnings ratio of 16.70 and a beta of 2.51. CareDx, Inc. has a one year low of $10.96 and a one year high of $24.56. The company has a 50 day moving average price of $19.74 and a 200 day moving average price of $16.55.

CareDx Company Profile

CareDx, Inc (NASDAQ: CDNA) is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non‐invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post‐transplant journey.

The company’s core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor‐derived cell‐free DNA assay used primarily in kidney transplant monitoring.